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Abstract 
Background: Degenerative aortic stenosis (AS), a disease of the elderly, frequently coexists with concomitant dis-
eases, including type 2 diabetes (T2DM) which amplifies the cardiovascular (CV) risk. T2DM affects left ventricular (LV) 
structure and function via hemodynamic and metabolic factors. In concentric LV geometry, typical for AS, indices of 
LV midwall mechanics are better estimates of LV function than ejection fraction (EF). Effects of T2DM coexisting with 
AS on circumferential LV midwall systolic function and large artery properties have not been reported so far. Our aim 
was to compare characteristics of AS patients with and without T2DM, with a focus on LV midwall systolic function 
and arterial compliance.
Methods: Medical records of 130 electively hospitalized patients with moderate or severe isolated degenerative AS 
were retrospectively analyzed. Exclusion criteria included clinical instability, atrial fibrillation, coronary artery disease 
and relevant non-cardiac diseases. From in-hospital echocardiography and blood pressure, we calculated LV midwall 
fractional shortening (mwFS), circumferential end-systolic LV wall stress (cESS) and valvulo-arterial impedance (Zva), 
estimates of LV afterload, as well as systemic arterial compliance.
Results: Patients with (n = 50) and without T2DM (n = 80) did not differ in age, AS severity, LV mass and LV dias-
tolic diameter. T2DM patients exhibited elevated cESS (247 ± 105 vs. 209 ± 84 hPa, p = 0.025) and Zva (5.8 ± 2.2 vs. 
5.1 ± 1.8 mmHg per mL/m2, p = 0.04), and lower stroke volume index (33 ± 10 vs. 38 ± 12 mL/m2, p = 0.01) and 
systemic arterial compliance (0.53 ± 0.16 vs. 0.62 ± 0.22 mL/m2 per mmHg, p = 0.01). mwFS (11.9 ± 3.9 vs. 14.1 ± 3.7%, 
p = 0.001), but not EF (51 ± 14 vs. 54 ± 13%, p = n.s.), was reduced in T2DM. mwFS and cESS were inversely inter-
related in patients both with (r = − 0.59, p < 0.001) and without T2DM (r = − 0.53, p < 0.001) By multiple regression, 
higher cESS (p < 0.001) and T2DM (p = 0.02) were independent predictors of depressed mwFS.
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Background
Degenerative aortic stenosis (AS), a disease of the elderly, 
frequently coexists with concomitant diseases includ-
ing type 2 diabetes (T2DM) which amplifies the risk of 
adverse cardiovascular (CV) events in asymptomatic 
patients [1] and after surgical aortic valve replacement 
[2]. Regardless of associations with coronary artery dis-
ease (CAD) and hypertension, T2DM per se is a risk 
factor for heart failure (HF) [3–6], influencing left ven-
tricular (LV) structure and function via multiple path-
ways, including large artery stiffening and direct effects 
on the myocardium with consequent enhanced LV 
hypertrophy and LV dysfunction [7–11].
Although a restrictive, not dilated, phenotype of dia-
betic cardiomyopathy predominates in T2DM without 
CV disease [10, 12, 13], slight impairment of LV systolic 
function despite normal ejection fraction (EF) appears 
also frequent, with combined systolic and diastolic dys-
function in 10–25% of T2DM patients without overt 
cardiac disease [14–16]. Of note, subclinical circumfer-
ential and/or longitudinal LV systolic dysfunction was 
reported in over one-half of T2DM patients free of CV 
disease [16]. Additionally, impaired stress-corrected 
LV midwall fractional shortening (mwFS), detected 
in almost 40% of T2DM subjects without CV disease, 
independently predicted CV mortality [17]. Moreover, 
depressed mwFS predisposed to adverse ischemic and 
aortic valve-related CV events in asymptomatic AS with 
a preserved EF [18].
To the best of our knowledge, effects of T2DM coex-
isting with AS on circumferential LV systolic function 
at the midwall level, a better estimate of LV func-
tion than EF at concentric LV geometry, typical for 
AS, have not been reported so far. As compared to 
non-diabetic patients with severe AS, in diabetic AS 
subjects Lindman et  al. [19] found reduced conven-
tional EF (i.e., at the endocardial level) and depressed 
longitudinal LV systolic function by strain-rate imag-
ing using the speckle tracking method, a trend toward 
impaired LV diastolic function by tissue Doppler, and 
similar systemic arterial compliance. On the other 
hand, Falcão-Pires et  al. [20] described significantly 
lower LV end-diastolic distensibility, enhanced inter-
stitial myocardial fibrosis and reduced cardiomyocyte 
passive stiffness in AS patients with versus without 
T2DM, undergoing perioperative LV biopsies, however 
the subgroups had similar EF. Our aim was to compare 
characteristics of AS patients with and without T2DM, 
with a focus on LV systolic function at the midwall level 
and systemic arterial compliance.
Methods
Patients
We retrospectively analyzed medical records of clini-
cally stable patients hospitalized on an elective basis in 
our center during 2013–2018 with a final diagnosis of 
isolated moderate or severe degenerative AS-defined as 
aortic valve area ≤ 1.5  cm2 (by the continuity equation), 
supported by additional measures (mean aortic pressure 
gradient, aortic valve area index and maximal aortic jet 
velocity) in case of any doubts with regard to AS severity, 
i.e. in accordance with an integrative approach to grading 
AS [21, 22]. Exclusion criteria included: more than mild 
aortic regurgitation or disease of another valve, atrial 
fibrillation, a history of myocardial infarction or coronary 
revascularization, diameter narrowings of ≥ 50% in major 
epicardial artery segments on coronary angiography, esti-
mated glomerular filtration rate < 30 mL/min per 1.73 m2 
(by the CKD-EPI formula), other relevant non-cardiac 
coexistent diseases except for T2DM and well-controlled 
hypertension, and the use of sodium-glucose co-trans-
porter 2 (SGLT-2) inhibitors or glucagon-like peptide 1 
receptor agonists.
On the basis of the exclusion criteria, out of 335 pre-
screened subjects, 130 AS patients in sinus rhythm with 
an adequate echocardiographic image quality and com-
plete data (50 with previously diagnosed T2DM and 80 
without diabetes) entered the final analysis.
Data extraction and additional calculations
In-hospital echocardiography was performed on an 
ultrasound device (Vivid 8; GE Healthcare, Chicago, IL, 
USA) by a recognized sonographer. From routine in-hos-
pital echocardiographic records we extracted EF, calcu-
lated from recorded 2D-images by means of the modified 
Simpson’s rule and validated by one of the senior authors, 
while LV mass was derived by the Devereux formula, 
in accordance with the current practice guidelines [23]. 
Additionally, from echocardiography and mean in-hospi-
tal blood pressure (computed from all in-hospital blood 
pressure measurements), we calculated valvulo-arterial 
impedance (Zva)—an index of the sum of valvular and 
arterial components of LV afterload, and systemic arterial 
compliance, as previously proposed [24]. Zva was derived 
Conclusions: In AS, coexistent T2DM appears associated with reduced systemic arterial compliance and LV dysfunc-
tion at the midwall level, corresponding to slightly depressed myocardial contractility.
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from systolic blood pressure, mean aortic pressure gra-
dient and stroke volume index, whereas systemic arterial 
compliance from stroke volume index and pulse pressure 
[24], as in our earlier reports [25, 26].
Also, in agreement with a simplified cylindrical LV 
model [27–29], from 2D-guided M-mode LV measure-
ments and blood pressure, mwFS and circumferential 
end-systolic LV midwall stress (cESS) at the LV minor axis, 
an estimate of afterload at the ventricular level, were com-
puted for the following reasons. First, vectors of LV mid-
wall stress and fiber shortening are oriented in the same 
direction because circumferential fibers predominate at 
the LV midwall equator, in contrast to the subendocardial 
layer where longitudinal fibers are more prevalent [28]. 
Second, as mwFS was derived on the basis of a constant 
volume of the myocardial “shell” between the midwall and 
the endocardium [27], the proposed approach takes into 
consideration systolic migration of midwall fibers from 
the middle line towards epicardium, providing a better 
index of LV performance than EF which overestimates LV 
function at concentric LV geometry [28].
As previously proposed [27], cESS and mwFS were cal-
culated according to the following formulas:
 where SBP is systolic blood pressure [mmHg],  PGmax: 
maximal transvalvular aortic pressure gradient [mmHg], 
LVd: LV end-diastolic diameter [cm]; LVs: LV end-systolic 
diameter [cm]; PWd: LV posterior wall thickness at end-
diastole; PWs: LV posterior wall thickness at end-systole 
[cm]; IVSd: interventricular septum thickness at end-
diastole [cm]; Hs/2: systolic LV inner shell myocardial 
thickness, computed in agreement with the assumption 
of a constant volume of the LV inner myocardial shell 
throughout the cardiac cycle [27], and 1.333 is a conver-
sion factor from mmHg into hPa.
Statistical analysis
Patients’ characteristics were compared between sub-
jects with and without T2DM by a 2-sided Student’s t 
test (or a Welch’s test for inhomogeneous variance) and 
the Chi square test for continuous and categorical data, 
respectively. The homogeneity of variance was verified 
by Levene’s test. Bivariate correlations were estimated 
by Pearson’s correlation coefficients (r). Multiple lin-
ear regression was used to identify independent deter-
minants of mwFS. Additionally, assuming low mwFS as 
cESS [hPa] = 1.333× (SBP+ PGmax) × (LVs/2)
2
×
[
1+
{
[(LVs/2)+ PWs]
2
/
[(LVs/2)+ (PWs/2)]
2
}]/{[
[(LVs/2)+ PWs]
2
−
(
LVs
/
2
)2]}
,
mwFS =
{
[(LVd + PWd/2+ IVSd/2)− (LVs + Hs/2)]
/
(LVd + PWd/2+ IVSd/2)
}
×100%,
mwFS < 14% in women and < 16% in men, we performed 
stepwise logistic regression with low mwFS as a dichot-
omous dependent variable, and the following potential 
predictors: cESS, systolic blood pressure, hypertension 
and metabolic syndrome, separately for diabetic and non-
diabetic AS patients. A p-value below 0.05 was assumed 
significant.
Results
Comparison of clinical and hemodynamic characteristics 
in aortic stenosis patients with and without concomitant 
T2DM
Patients with and without T2DM did not differ in clini-
cal characteristics except for higher body-mass index in 
T2DM (Table 1).
Patients’ hemodynamic characteristics by T2DM sta-
tus are shown in Table  2. The severity of AS, estimated 
by aortic valve area index and mean aortic pressure gra-
dient, was comparable in patients with and without con-
comitant T2DM (Fig. 1a). There were also no intergroup 
differences in LV end-diastolic diameter and LV mass 
index (Fig. 1b). Both measures of LV afterload, cESS and 
Zva were elevated in T2DM (Fig.  1c), whereas systemic 
arterial compliance was depressed, due to a lower stroke 
volume index (Fig.  1d) at a similar pulse pressure. Of 
note, mwFS—but not EF—was significantly reduced in 
T2DM (Fig. 1e).
Comparison of the relationship between mwFS and cESS 
in aortic stenosis patients with and without concomitant 
T2DM
mwFS and cESS were negatively related with each other 
in patients with T2DM (r = − 0.59, p < 0.001) and with-
out T2DM (r = − 0.53, p < 0.001) (Fig.  2). mwFS, plotted 
against cESS, was lower in AS with T2DM compared to AS 
without T2DM for each given value of cESS (Fig. 2). This 
effect was confirmed by multiple regression: mwFS was 
depressed in T2DM subjects (mean β ± SEM: −0.17 ± 0.07, 
p = 0.02), independently of a strong inverse association 
between mwFS and cESS (β = − 0.54 ± 0.07, p < 0.001).
As a continuous variable, mwFS was unrelated to any 
other patients’ characteristics than cESS, including also 
systemic arterial compliance or symptomatic status in 
either diabetic AS subjects, their non-diabetic counter-
parts or the whole study group (p > 0.15).
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By stepwise logistic regression, exclusively increased 
cESS independently predicted low mwFS, when analyz-
ing diabetic and non-diabetic AS patients separately 
(mean odds ratio [OR] per 10-hPa increment: 1.11 [con-
fidence interval: 1.01–1.23], p = 0.035 for subjects with 
T2DM; OR = 1.13 [1.05–1.21], p = 0.001 for subjects 
without diabetes).
Discussion
Our salient finding was reduced systemic arterial compli-
ance and lower mwFS, reflecting LV systolic performance 
at the midwall level, which was not entirely explained by 
higher cESS, an index of LV afterload, in patients with 
moderate or severe AS and concomitant T2DM.
Comparison with other studies
The prevalence of low mwFS was 78% in our AS patients 
with concomitant T2DM, i.e. higher than the respec-
tive proportion (34–52%) of subjects with impaired LV 
midwall systolic function among T2DM patients with-
out overt CV disease, participating in the DYDA [15] 
and SHOCKWAVE [16] studies. However, none of those 
T2DM subjects exhibited significant valvular heart dis-
ease [15, 16], whereas our patients had AS and T2DM, 
both of which predispose to LV systolic dysfunction 
and have been referred to as “an ominous combination” 
by Banovic et  al. [30]. The proportion of impaired cir-
cumferential LV systolic function at the midwall level 
was 24%, 28% and 30% in normal weight, overweight 
and obese non-diabetic patients with mild or moderate 
asymptomatic isolated AS in the SEAS cohort [31], and 
71% in asymptomatic severe AS, whose vast majority 
(94%) was free of diabetes [1]. Because our AS subjects 
had moderate or severe AS and were mainly overweight 
or obese, the high prevalence (60%) of low mwFS even in 
our AS patients without diabetes is generally consistent 
with those reports [1, 31].
Notably, diabetic subjects were excluded from the 
SEAS [31] and ASTRONOMER [32] studies, which 
investigated determinants of longitudinal [32] and cir-
cumferential midwall [31] LV systolic function in large 
groups of patients with mild or moderate asymptomatic 
isolated AS. Moreover, Lindman et al. [19], who reported 
longitudinal LV systolic dysfunction by strain-rate imag-
ing by means of the speckle tracing method in severe AS 
with versus without concomitant diabetes, did not ana-
lyze circumferential midwall LV function, and did not 
adjust peak longitudinal systolic strain for LV afterload. 
Therefore, our study is first to demonstrate associations 
of T2DM with subclinical circumferential LV systolic dys-
function at the midwall level AS, irrespective of higher 
cESS. Accordingly, this finding supplements earlier 
Table 1 Clinical characteristics in patients with and without 
concomitant T2DM
Data are shown as mean ± SD or n (%)
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor 
blockers
a A history of heart failure, syncope or angina linked to AS
Characteristic T2DM
n = 50
No diabetes
n = 80
p value
Age (years) 70 ± 9 70 ± 11 n.s.
Men/Women, n (%) 23/27 (46/54%) 44/36 (55/45%) n.s.
Symptoms, n (%)a 31 (62%) 41 (51%) n.s.
Hypertension, n (%) 45 (90%) 62 (78%) n.s.
Chronic kidney disease, n 
(%)
16 (32%) 17 (21%) n.s.
Body-mass index (kg/m2) 31 ± 5 28 ± 4 0.003
Mean blood pressure (mm 
Hg)
90 ± 10 89 ± 10 n.s.
Systolic blood pressure (mm 
Hg)
131 ± 16 130 ± 18 n.s.
Glycated hemoglobin (%) 7.1 ± 0.8 – –
Medications, n (%)
 ACEI or ARB 30 (60%) 43 (54%) n.s.
 Beta-blocker 25 (50%) 34 (43%) n.s.
 Diuretic 20 (40%) 27 (34%) n.s.
 Calcium channel blockers 17 (34%) 24 (30%) n.s.
 Statin 38 (76%) 50 (62%) n.s.
 Metformin 47 (94%) – –
 Insulin 16 (32%) – –
Table 2 Hemodynamic characteristics of  AS  patients 
with and without concomitant T2DM
Data are shown as mean ± SD
cESS circumferential end-systolic LV midwall stress, LV left ventricular, Zva 
valvulo-arterial impedance
Characteristic T2DM
n = 50
No diabetes
n = 80
p value
Aortic valve area index  (cm2/
m2)
0.50 ± 0.17 0.52 ± 0.16 n.s.
Mean aortic pressure gradient 
(mm Hg)
41 ± 24 40 ± 21 n.s.
LV end-diastolic diameter (cm) 5.1 ± 0.9 5.1 ± 1.0 n.s.
LV mass index (g/m2) 143 ± 41 152 ± 62 n.s.
LV ejection fraction (%) 51 ± 14 54 ± 13 n.s.
LV midwall fractional shorten-
ing (%)
11.9 ± 3.9 14.1 ± 3.7 0.001
Low LV midwall fractional 
shortening, n (%)
39 (78%) 48 (60%) 0.03
Stroke volume index (mL/m2) 33 ± 10 38 ± 12 0.01
cESS (hPa) 247 ± 105 209 ± 84 0.025
Zva (mm Hg per mL/m2) 5.8 ± 2.2 5.1 ± 1.8 0.04
Pulse pressure (mm Hg) 63 ± 14 64 ± 17 n.s.
Systemic arterial compliance 
(mL/m2 per mm Hg)
0.53 ± 0.16 0.62 ± 0.22 0.01
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evidence from the Multi-Ethnic Study of Atherosclerosis 
(MESA) which detected an association of diabetes with 
regional LV systolic dysfunction by circumferential strain 
imaging in four LV midwall segments using cardiac mag-
netic resonance in subjects without clinically recognized 
CV disease [33].
Fig. 1 Hemodynamic characteristics by T2DM status. a Aortic valve area index and mean aortic pressure gradient; b LV end-diastolic diameter, a raw 
estimate of LV preload, and LV mass index; c circumferential end-systolic LV midwall stress and valvulo-arterial impedance, indices of LV afterload; d 
systemic arterial compliance and LV stroke volume index; e LV midwall fractional shortening and ejection fraction. Data are shown as mean ± SD
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Keeping in mind numerous reports of elevated arterial 
stiffness and reduced vascular compliance in T2DM [11], 
lower systemic arterial compliance in our diabetic AS 
subjects does not appear unexpected, although Lindman 
et al. [19] did not observed a significant difference in this 
parameter according to diabetes status in severe AS.
Mechanistic considerations
Our preliminary observations, based on a retrospective 
cross-sectional data analysis, allows only cautious inter-
pretations in term of possible mechanisms. Nevertheless, 
as metabolic factors have been implicated in the patho-
genesis of both diabetic cardiomyopathy and altered 
vascular properties, multiple detrimental pathways are 
likely to contribute to CV damage also in AS [9–11, 30, 
34, 35]. That, in contrast to previously reported associa-
tions of poor glycemic control with lower ascendic aortic 
distensibility [36] and higher aortic pulse wave velocity in 
T2DM [37], systemic arterial compliance was unrelated 
to glycated hemoglobin in our diabetic AS subjects, might 
be due to multifactorial nature of vascular abnormalities 
in T2DM, including not only deposition of advanced gly-
cation end-products, but also insulin resistance, impaired 
nitric oxide bioavailability, oxidative stress, enhanced 
fibrosis and inflammatory activation [11, 30]. Likewise, a 
variety of mechanisms underlying CV damage in T2DM 
[9–11, 30, 34, 35, 38] could be accountable for no rela-
tions between symptomatic status, systemic arterial com-
pliance and LV function in the present study.
Additionally, in the SEAS [31] and ASTRONOMER 
[32] studies, subclinical circumferential [31] and longi-
tudinal [32] LV systolic dysfunction was reported already 
in non-diabetic AS patients with concomitant metabolic 
syndrome [32] or obesity [31], well-known predecessors 
of T2DM, and metabolic syndrome was associated with 
marginally lower systemic arterial compliance in the 
ASTRONOMER cohort [32], which points into the rel-
evance of insulin resistance/hyperinsulinemia, accompa-
nied by altered myocardial substrate metabolism (a shift 
from glucose to fatty acids oxidation) and chronic low-
grade inflammatory activation [10, 34, 35, 38], for cardiac 
and vascular damage before the onset of T2DM. This 
concept is also consistent with a lower stress-corrected 
mwFS in adolescents and young adults with impaired 
fasting glucose, i.e. prediabetic state, compared to those 
with normal glucose tolerance in the Strong Heart Study 
[39]. Moreover, insulin resistance was identified as an 
independent correlate of reduced large artery compli-
ance in asymptomatic young adults participating in the 
Bogalusa Heart Study [40]. Accordingly, that we observed 
the coexistence of reduced mwFS and systemic arte-
rial compliance in our AS patients with versus without 
T2DM, might indicate a highly adverse constellation [30] 
(probably present for many years before T2DM onset) 
accountable for consequent depressed stroke volume 
index, also found in our diabetic AS subjects. Notably, as 
systolic blood pressure, mean aortic gradient and pulse 
pressure were similar according to T2DM status, reduced 
stroke volume index was largely responsible for increased 
Zva and decreased systemic arterial compliance in our 
AS patients with concomitant T2DM. Importantly, low 
stroke volume index, an independent predictor of inci-
dent HF in the Strong Heart Study population [41], is 
also a hallmark of increased risk of mortality in severe 
AS with preserved EF [42] and after transcatheter aortic 
valve implantation [43].
Aortic stenosis with concomitant T2DM – a clinical 
challenge
Patients with both AS and T2DM are a specific group 
because renin-angiotensin system inhibitors, a power-
ful tool for cardioprotection and nephroprotection in 
T2DM, are perceived as relatively contraindicated in 
severe AS, due to the putative risk of hypotension. There-
fore, alternative strategies to improve CV outcome are 
necessary in patients with combined AS and T2DM, in 
whom the risk of adverse CV events is elevated by 4- to 
sixfold in asymptomatic severe AS [1], renin-angioten-
sin antagonists are frequently underused, while surgical 
or transcatheter aortic valve implantation are limited 
to subjects with recognized indications to these proce-
dures. Keeping in mind the potential relevance of meta-
bolic factors for CV damage in AS with coexistent T2DM 
[30], optimized long-term glycemic control and lifestyle 
interventions in T2DM and prediabetes might modulate 
a corollary of detrimental pathways which contribute to 
Fig. 2 LV midwall fractional shortening plotted against 
circumferential end-systolic LV midwall stress in AS patients with and 
without T2DM
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accelerated development of HF in patients with com-
bined AS and T2DM.
Irrespective of the degree of glycemic control, novel 
antidiabetic drugs such as SGLT-2 inhibitors—recom-
mended for patients with T2DM and established CV 
disease, especially HF [44]—can have a potential to 
improve prognosis also in AS. Hypothetically, the abil-
ity of SGLT-2 inhibitors to prevent both development of 
HF and HF hospitalizations in patients with prevalent HF 
[44], linked to multiple mechanisms, including reduced 
LV loading conditions and decreased arterial stiffness 
[35, 44–48], could translate into delayed onset of symp-
toms in AS patients on medical therapy. Nevertheless, 
CV effects of SGLT-2 antagonists in T2DM with con-
comitant AS still remain to be investigated.
Finally, reduced mwFS or depressed systemic arte-
rial compliance might possibly be helpful in risk strati-
fication of asymptomatic AS subjects with concomitant 
T2DM. In fact, subclinical circumferential LV midwall 
dysfunction was independently related to incident HF 
over a 5-year follow-up in the MESA participants free 
of known CV disease, irrespective of diabetes status and 
end-systolic LV wall stress [33]. In addition, aortic pulse 
wave velocity was independently related to pre- and post-
operative NYHA class in AS subjects undergoing surgical 
valve replacement [49]. Nevertheless, large-scale pro-
spective studies are warranted to assess potential clini-
cal utility of measures of arterial stiffness or compliance, 
as well as novel indices of LV function, such as mwFS or 
recently proposed diastolic wall strain [50] in asympto-
matic AS patients.
Study limitations
First, our findings have been based on a single-center 
retrospective analysis of medical records of patients 
hospitalized for AS, in whom the diagnosis of T2DM 
had been established prior to admission. Nevertheless, 
T2DM diagnosis has been verified in any dubious cases. 
Additionally, in order to increase the homogeneity of 
the study population, we had excluded subjects with 
relevant non-cardiac disorders and underlying cardiac 
pathology other than pure AS, especially without CAD. 
Second, novel echocardiographic techniques, such as tis-
sue Doppler or strain imaging, are appropriate for the 
quantification of subclinical LV dysfunction, however, we 
were only able to compute mwFS from available routine 
echocardiographic records, and exclusively good-quality 
images entered the final analysis. Third, systemic arte-
rial compliance was estimated by a simple index derived 
from stroke volume index and pulse pressure, whereas 
a complex approach, including arterial tonometry, pres-
sure-flow analysis and 24-h blood pressure monitoring, 
is more suitable to investigate arterial properties, all the 
more because Chirinos et  al. [51] have recently demon-
strated the association of T2DM with arterial stiffening 
and abnormal pulsatile arterial hemodynamics in HF 
with preserved EF. Fourth, medical therapy was not uni-
form in the study group. Nonetheless, the proportion of 
renin-angiotensin system antagonists and beta-blockers 
was similar in patients with and without T2DM, almost 
all T2DM subjects were on metformin and none of them 
was receiving SGLT-2 inhibitors or glucagon-like peptide 
1 receptor agonists. Finally, owing to limited availability 
of longitudinal medical records, we were unable to inves-
tigate either the previously suggested effect of T2DM 
on the progression of AS severity [30] or AS-related 
outcomes.
Conclusions
In AS, coexistent T2DM appears associated with reduced 
systemic arterial compliance and impaired LV systolic 
function at the midwall level, corresponding to slightly 
depressed myocardial contractility. Further studies are 
warranted to investigate possible strategies which might 
improve LV performance and delay onset of symptoms in 
AS with concomitant T2DM.
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